
-
C4 Therapuetics NASDAQ:CCCC C4 Therapeutics is a biopharmaceutical company focused on harnessing the body’s natural regulation of protein levels to develop novel therapeutic candidates to target and destroy disease-causing proteins for the treatment of cancer and other diseases. This targeted protein degradation approach offers advantages over traditional therapies, including the potential to treat a wider range of diseases, reduce drug resistance, achieve higher potency, and decrease side effects through greater selectivity.
Location: | Website: www.c4thera.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing
Market Cap
NaN
52 Wk Range
$ - $
Previous Close
$N/A
Open
$N/A
Day Range
N/A - N/A
Volume
N/A
Avg Volume
N/A
Enterprise Value
23.93M
Cash
255.6M
Avg Qtr Burn
-17.81M
Short % of Float
15.80%
Insider Ownership
11.57%
Institutional Own.
92.01%
Qtr Updated
09/30/24
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Cemsidomide (CFT7455) +/- dexamethasone Details Hematologic malignancies, Blood disorder, Non-Hodgkin lymphoma, Blood cancer, Multiple myeloma | Phase 1/2 Data readout | |
CFT1946 Details Cancer, Solid tumor/s | Phase 1/2 Data readout | |
CFT8919 (EGFR) Details Solid tumor/s, Non-small cell lung carcinoma, Cancer | Phase 1 Data readout | |
CFT8634 (BiDAC) Details Rare diseases, Cancer | Failed Discontinued |